TL;DR
This study reveals that Interleukin-17 (IL-17), primarily produced by T helper 17 (T<sub>H</sub>17) cells, plays a crucial protective role in preventing nonalcoholic steatohepatitis (NASH) by maintaining intestinal barrier integrity. IL-17 deficiency leads to gut dysbiosis, increased intestinal permeability, and exacerbated NASH, highlighting IL-17 as a potential therapeutic target.
What Problem Does This Paper Address?
Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic steatohepatitis (NASH), are growing global health concerns with limited treatment options. While the gut microbiota is known to influence NAFLD/NASH, the precise mechanisms, particularly the role of specific immune mediators like Interleukin-17 (IL-17), remain unclear. Previous studies have shown conflicting results regarding IL-17's role, with some suggesting it promotes NASH and others indicating a protective effect. This paper aims to elucidate how IL-17, in conjunction with the gut microbiota, impacts the development and progression of NASH, focusing on its role in maintaining intestinal barrier function.
Methods
The researchers employed a multi-pronged approach using mouse models and various experimental techniques:
- Diet-Induced NASH Model: Methionine-choline-deficient (MCD) diet was used to induce NASH in wild-type (WT) and IL-17-deficient ( Il17<sup>-/-</sup> ) mice.
- Immune Cell Profiling: Flow cytometry was used to quantify T<sub>H</sub>17 cells and other immune cell subsets in the liver and intestinal tissues.
- Gut Microbiota Analysis: 16S rRNA gene sequencing was performed to assess the composition and diversity of the gut microbiota.
- Intestinal Permeability Assays: Plasma levels of DX-4000-FITC (a marker for intestinal permeability) and serum lipopolysaccharide (LPS) levels (indicating endotoxemia) were measured.
- Histological Analysis: Hematoxylin and eosin (H&E) staining and Oil Red O staining were used to assess liver steatosis, inflammation, and fibrosis. Colon and small intestine tissues were also examined for structural integrity.
- Gene Expression Analysis: Quantitative PCR (qPCR) was used to measure the mRNA levels of key genes related to intestinal barrier function (e.g., Reg3y, Reg3β, Claudin-2, ZO-1).
- Cell Transfer Studies: Naïve CD4<sup>+</sup> T cells from WT or Il17<sup>-/-</sup> mice were transferred into Rag1<sup>-/-</sup> mice to assess the role of T<sub>H</sub>17 cells.
- Recombinant Protein Treatment: Exogenous recombinant IL-17A (rIL-17A) was administered to Il17<sup>-/-</sup> mice to evaluate its direct effects.
- Fecal Microbiota Transplantation (FMT): Feces from WT mice were transplanted into Il17<sup>-/-</sup> mice to investigate the impact of a healthy microbiota.
- Antibiotic Treatment (Abx): Antibiotics were used to deplete the gut microbiota in WT and Il17<sup>-/-</sup> mice to assess the microbiota's role in IL-17-mediated effects.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- IL-17's Protective Role in NASH: Contrary to some previous findings, this study strongly suggests that IL-17 is protective against diet-induced NASH, primarily by maintaining intestinal barrier integrity.
- Gut Microbiota as a Mediator: IL-17 deficiency leads to significant alterations in the gut microbiota, favoring pathogenic bacteria and inhibiting beneficial ones. This dysbiosis, in turn, contributes to increased intestinal permeability and NASH.
- T<sub>H</sub>17 Cells as the Source: The study pinpoints T<sub>H</sub>17 cells as the main source of IL-17 involved in these protective mechanisms, with their numbers decreasing in the small intestine during NASH.
- Intestinal Barrier as the Key Link: The research highlights the intestinal barrier as a critical interface where IL-17's influence on the microbiota translates into systemic effects on liver health.
- Restoration of Barrier Function: Administration of recombinant IL-17 or transplantation of a WT microbiota could restore intestinal barrier function and ameliorate NASH in IL-17-deficient mice.
Key Results
- IL-17 Deficiency Worsens NASH: Il17<sup>-/-</sup> mice fed an MCD diet exhibited more severe hepatic steatosis, inflammation, and fibrosis compared to WT mice. They also showed significantly higher endotoxemia and more pronounced intestinal barrier defects.
- Gut Dysbiosis in Il17<sup>-/-</sup> Mice: MCD diet-fed Il17<sup>-/-</sup> mice displayed altered gut microbiota with an increase in pathogenic bacteria (e.g., Proteobacteria, Enterobacteriaceae) and a decrease in beneficial bacteria (e.g., Oscillospira).
- IL-17 Restores Barrier Function: Treatment with rIL-17A in Il17<sup>-/-</sup> mice significantly improved colon barrier integrity, reduced submucosal edema and erosion, and normalized expression of tight junction proteins (ZO-1 and Claudin-2).
- T<sub>H</sub>17 Cell Transfer: Transferring CD4<sup>+</sup> T cells from WT mice to Rag1<sup>-/-</sup> mice improved intestinal barrier function and reduced NASH, while transfer from Il17<sup>-/-</sup> mice did not.
- FMT Reverses Effects: FMT from WT mice to Il17<sup>-/-</sup> mice restored intestinal barrier integrity and ameliorated NASH, demonstrating the microbiota's role. Conversely, FMT from Il17<sup>-/-</sup> mice to microbiota-depleted WT mice worsened intestinal barrier impairment and NASH.
- Antibiotic Treatment: Antibiotic treatment in Il17<sup>-/-</sup> mice significantly reduced intestinal permeability and endotoxemia, suggesting that the microbiota is the primary driver of these defects in the absence of IL-17.
Limitations and Future Work
The authors acknowledge that the precise mechanisms by which IL-17 influences specific bacterial taxa and how these changes impact the intestinal barrier require further investigation. Future work could focus on identifying the specific bacterial species that are modulated by IL-17 and how they interact with the intestinal epithelium. Additionally, determining whether live bacteria translocate to extraintestinal tissues, particularly the liver, in Il17<sup>-/-</sup> mice is an important avenue for future research. Understanding these intricate interactions could pave the way for novel therapeutic strategies targeting the gut microbiota and IL-17 pathway for NASH treatment.
Summary updated